Space calendar 2025: Rocket launches, skywatching events, missions & more!
2025 is a busy year for spaceflight and exploration with countless launches, mission milestones, industry conventions and skywatching events to look forward to.
With so much going on, it's hard to keep track of everything. Never fear — keep up with the latest events in our 2025 space calendar. You can also Find out what's up in the night sky this month with our visible planets guide and skywatching forecast.
Please note: Launch dates are subject to change and will be updated throughout the year as firmer dates arise. Please DO NOT schedule travel based on a date you see here. Launch dates are collected from NASA events, ESA news, Roscosmos space launch schedule, Spaceflight Now launch schedule, Everyday Astronaut, Supercluster and others.
Related: Wondering what happened today in space history? Check out our "On This Day in Space" video!
Is there a rocket launch today?
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Rocket Lab Stock Soars Higher as Neutron's Maiden Flight Nears
Rocket Lab Corp. RKLB is currently on the cusp of a transformative milestone with its highly anticipated Neutron rocket approaching its maiden flight in the second half of 2025. To expand beyond its small-launcher Electron and capture the medium-lift payload market, while positioning itself to compete with heavy-lift providers like SpaceX, Rocket Lab launched the Neutron program. This medium-class, reusable vehicle, with a potential payload capacity of approximately 15,000 kg, aims to offer flexible, cost-effective access to space for a wide range of customers, including satellite constellations, government missions, and commercial payloads. To this end, it is imperative to mention that in May 2025 Rocket Lab announced that it will launch its Neutron rocket for the U.S. Air Force Research Laboratory for a Rocket Cargo mission to support point-to-point cargo transportation, establishing a new era of commercial launch capability to advance global defense logistics for the nation. Earlier in February, the company revealed details about the ocean landing platform, a modified barge, for Neutron missions returning to Earth. Customized modification is currently ongoing on this barge, including autonomous ground support equipment to capture and secure the landed Neutron, blast shielding to protect equipment during Neutron landings, and station-keeping thrusters for precise positioning. These announcements implying consistent progress in the Neutron program have bolstered investor confidence, reflected in Rocket Lab's share price performance. While the company's year-to-date price increase has been modest, the past three months have seen a sharper uptick, underscoring growing optimism around Neutron's prospects as new milestones mentioned above are achieved. RKLB's shares gained 40% year to date, while the same soared 103.6% over the past three months. The space launch services market has been witnessing solid growth trends driven by surging demand for satellite constellations, increasing government and defense investments, and the growing need for low-cost, reliable access to space to support telecommunications, Earth observation, and national security missions. Therefore, investors interested in this business realm may keep RKLB along with other industry players like Boeing BA and Lockheed Martin LMT in their watchlist, which already enjoy an established footprint in the space launch market. Boeing's products have powered human space exploration for six decades now. The company is the prime contractor for the design, development and production of the core stage, upper stages and flight avionics suite used in NASA's Space Launch System, the only proven deep-space optimized, super-heavy lift rocket built to carry astronauts and cargo farther and faster than any rocket in history. Lockheed Martin is another space stock that has contributed significantly to various space missions with its breakthrough technologies. It is the prime contractor involved in the construction of Orion, the spacecraft that will carry the crew of four astronauts in the Artemis II lunar mission. Shares of RKLB have gained 630.8% in the past year compared with the industry's 50.9% growth. Image Source: Zacks Investment Research With respect to valuation, the company trades at a premium. RKLB currently trades at a forward 12-month Price/Sales of 22.49X compared with its industry's average of 10.06X. Image Source: Zacks Investment Research The Zacks Consensus Estimates for RKLB's 2025 and 2026 loss have improved over the past 60 days. Image Source: Zacks Investment Research RKLB stock currently carries a Zacks Rank #4 (Sell). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report The Boeing Company (BA) : Free Stock Analysis Report Lockheed Martin Corporation (LMT) : Free Stock Analysis Report Rocket Lab Corporation (RKLB) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
CBS News
2 hours ago
- CBS News
Detecting, monitoring skin cancers made easier with new screening technology
According to the American Cancer Society, more than 100,000 people will be diagnosed with melanoma this year. The good news is now that treatments have advanced, death rates have declined. Diagnostic tools have also vastly improved to detect and monitor skin cancers. Vectra WB180 system takes just seconds to photograph spots Dr. Jonathan Unger, medical director of the Waldman Melanoma and Skin Cancer Center at Mount Sinai, showed CBS News New York the Vectra WB180 system. "Basically, it is a total body photography system," Unger said. "We use 26 cameras to photograph the entire body ... And then the system takes all of these photos, high-resolution photos, and stitches them together into a three-dimensional avatar." The Vectra WB180 system uses 26 cameras to photograph the entire body so doctors can monitor spots on patients' skin. CBS News New York This is relatively new screening technology with about 100 machines across the country. Unger says it takes just a matter of seconds instead of all the time necessary to photograph each individual spot. "Gives us a memory of every spot on the patient's body, right? Once we have a moment in time, we can always look back and say, what did this thing look like? Was it there? Was it not there? Has it been changing?" he said. He adds accessing details of a patient's mole is much quicker, again, taking only seconds. There are additional benefits to this technology, as well. "Decide with greater certainty and more information whether something needs to be checked, tested, biopsied, et cetera," he said. "In our practice, it's really reduced the number of biopsies because a lot of our patients have hundreds, if not more than that, moles, all of which are irregular." He continued, "This allows us to have a higher level of confidence about what we're looking at and making a decision about." "It gives me the ability to take a deep breath and enjoy my life" Patient Jackie Mills has her spots scrutinized with the new machine after a scare several years ago. "In about 2020, I noticed a spot on my face that was new and rapidly changing," she said. But Mills says her dermatologist at that time wasn't that concerned. "I felt like it was getting bigger, changing colors, it was more jagged, and I really had to push and advocate for myself," she said. "Just had a gut feeling that something was wrong, and I was right." Mills was finally diagnosed with melanoma and had Mohs surgery to have the spot removed. "I had to kind of take it in for a minute and be like, I'm going to have a scar on my face for the rest of my life," she said. "It was that or not be here." Now she's checked every six months. "Not only is Dr. Unger looking at my spots, but he's using this machine to mathematically track what's going on from year to year. And I think that's just, it gives me the ability to take a deep breath and enjoy my life and not be constantly worried about melanoma coming back or being an issue," Mills said. The biggest safety tip from doctors is to use sunscreen every day. It can help prevent sunburn, premature aging and skin cancer.
Yahoo
4 hours ago
- Yahoo
Ready-made stem cell therapies for pets could be coming
Earlier this week, San Diego startup Gallant announced $18 million in funding to bring the first FDA-approved ready-to-use stem cell therapy to veterinary medicine. If it passes regulatory muster, it could create a whole new way to treat our fur babies. It's still an experimental field, even though people have been researching stem cells for humans for decades. Seven-year-old Gallant's first target is a painful mouth condition in cats called Feline Chronic Gingivostomatitis (FCGS), which Gallant says could receive FDA approval by early 2026. The field has shown some encouraging early results. Studies on dogs with arthritis showed improvements in pain and mobility, with some benefits lasting up to two years. But when researchers tried similar treatments for kidney disease in cats — that's another condition Gallant wants to tackle — the results were more mixed. What makes Gallant's approach different is convenience. Most stem cell treatments today require harvesting cells from the patient or donors with matching tissue, whereas Gallant's therapy uses ready-to-use cells from donor animals, even if they are a different species. Investors clearly see potential here. The funding round was led by existing backer Digitalis Ventures, with participation from NovaQuest Capital Management, which previously invested in the first FDA-approved human stem cell therapy. The company has an interesting backstory. Gallant's founder, Aaron Hirschhorn, previously sold DogVacay to its biggest rival in the dog-sitting marketplace, Rover. Hirschhorn passed away in 2021; Gallant is now led by Linda Black, who joined as its president and chief scientific officer from nearly the beginning. Gallant has now raised at least $44 million altogether from investors. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
